Summary
Becton, Dickinson and Company (BDX) reported fiscal year 2023 revenues of $19.372 billion, a 2.7% increase over the prior year, driven by volume growth and pricing, although partially offset by a decline in COVID-19-related testing sales and foreign currency translation impacts. The company's strategic objectives for value creation are centered around growing its portfolio, simplifying operations, and empowering its workforce. Despite inflationary pressures on raw materials, labor, and energy, BD maintained strong operating cash flows and returned value to shareholders through dividends. Key areas of focus include innovation in smart devices, expanding global access to medical technologies, and enhancing operational efficiencies. However, the company continues to navigate challenges, including the ongoing remediation efforts related to its Alaris™ infusion pumps, which significantly impacted the Medical segment's operating income, and the broader impacts of global macroeconomic conditions and geopolitical factors. BDx operates across three main segments: Medical, Life Sciences, and Interventional, each contributing to its diverse product offerings. The company remains committed to investing in research and development to maintain its competitive edge in the dynamic medical technology landscape.
Financial Highlights
56 data points| Revenue | $19.37B |
| Cost of Revenue | $11.20B |
| Gross Profit | $8.17B |
| R&D Expenses | $1.24B |
| SG&A Expenses | $4.72B |
| Operating Expenses | $17.26B |
| Operating Income | $2.11B |
| Interest Expense | $452.00M |
| Net Income | $1.48B |
| EPS (Basic) | $4.97 |
| EPS (Diluted) | $4.94 |
| Shares Outstanding (Basic) | 286.28M |
| Shares Outstanding (Diluted) | 288.39M |
Key Highlights
- 1BDX reported fiscal year 2023 revenues of $19.372 billion, a 2.7% increase year-over-year, driven by volume, pricing, and acquisitions, though impacted by a decline in COVID-19 testing revenues.
- 2The Medical segment saw a 7.5% revenue increase, primarily due to strong catheter sales and growth in Medication Management Solutions (including Parata Systems acquisition) and Pharmaceutical Systems.
- 3The Life Sciences segment experienced a 7.8% revenue decrease, largely due to a significant drop in COVID-19-only diagnostic testing sales, partially offset by growth in Biosciences.
- 4The Interventional segment reported a 6.1% revenue increase, led by strong performance in Surgery and Peripheral Intervention, despite the divestiture of the Surgical Instrumentation platform.
- 5The company's cash flow from operations remained robust at $2.990 billion, supporting continued shareholder returns through dividends.
- 6Significant remediation costs related to Alaris™ infusion pumps impacted the Medical segment's operating income, with $653 million charged in fiscal year 2023.
- 7BDX continues to manage global macroeconomic challenges, including inflation and supply chain disruptions, through various cost-mitigation strategies and investments in operational efficiency.